Knee osteoarthritis (KOA) is a painful joint condition that has a global prevalence of over 300 million as of 2023, according to the World Health Organization. Arthrosamid is an injection that allows those who suffer from KOA to receive minimally invasive treatment that will last long term. The Observational Clinical Investigation of Arthrosamid in Knee Osteoarthritis (LUNA) trial, conducted in Europe, follows the long-term effects of patients who received Arthrosamid, assessing pain, stiffness, and physical function. The recently published one-year results from the LUNA study showed that no patients experienced serious adverse events from treatment, suggesting that Arthrosamid may offer a promising minimally invasive option for KOA, says GlobalData, a leading data and analytics company.

According to GlobalData, the global knee reconstruction market was valued at over $10 billion in 2024. It is expected to continue rising as indications for KOA increase in prevalence. Contura, the manufacturer of Arthrosamid, does not hold a majority market share in the knee reconstruction market. Currently available in Europe, Canada, and New Zealand, this innovation may give them a wider reach globally.  

Amy Paterson, Medical Analyst at GlobalData, comments: “Minimally invasive treatment that has long-lasting effects could take strain off hospitals. As more people are diagnosed with KOA, access to minimally invasive outpatient treatment allows more patients to be treated every day.”

The LUNA study also showed that pain improved, and side effects quickly subsided. Current results of the study state that KOA symptoms improved over one year. The data shows that KOA symptoms are relieved for up to three years. Patient progress will continue to be monitored for up to five years.

Paterson concludes: “Minimally invasive treatments will likely be the preferred method of treatment in many different surgical areas. They provide a lower cost, faster recovery option than many surgeries. Minimally invasive treatments may also allow for patients to treat KOA earlier, instead of trying many other options that do not provide long-term relief.”